Human telomerase reverse transcriptase protein expression predicts tumour aggressiveness and survival in patients with clear cell renal cell carcinoma by Saeednejad Zanjani, L. et al.
Human telomerase reverse transcriptase protein expression predicts tumor 
aggressiveness and survival in patients with clear cell renal cell carcinoma 
 
Leili Saeednejad Zanjani 1, Zahra Madjd, 1,2*, Maryam Abolhasani 1,3, Arezoo Rasti 
1,  Ahmad Shariftabrizi4 , Mojgan Asgari *1,3Fint om du sender fulltekst på den i listen så vi får 
godkjent den  
 
1. Oncopathology Research Centre, Iran University of Medical Sciences (IUMS), Tehran, Iran. 
2. Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran 
University of Medical Sciences, Tehran, Iran. 
3. Hasheminejad Kidney Center, Iran University of Medical Sciences, (IUMS), Tehran, Iran. 
4. Department of Nuclear Medicine and Molecular Imaging, State University of New York at 
Buffalo, Buffalo, NY 14223, USA. 
 
*Corresponding authors:  
Zahra Madjd (MD, PhD)  
Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Hemmat Street 
(Highway), Next to Milad Tower, Tehran14496-14530, Iran. 
Phone: +982186703212  
Fax: +982188622608 
Email: Zahra.madjd@yahoo.com  




Acknowledgments: This research was supported by a grant from Iran University of Medical 
Sciences (Grant #25153). 
Conflict of interest: The authors declare no conflict of interest. 
Ethical approval: The study was approved by the Iran University of Medical Sciences. All 
procedures performed in this study were in accordance with the 1964 Helsinki Declaration and 
its later amendments. 
 
Informed consent: It was obtained at the time of sample collection in routine consent forms. 
Abstract 
Human telomerase reverse transcriptase (hTERT) is an active component of telomerase and 
responsible for its catalytic activity, associated with cell proliferation and differentiation. The 
present study, for the first time was conducted to evaluate the expression and prognostic 
significance of hTERT in different histological subtypes of renal cell carcinoma (RCC). 
Expression of hTERT was examined in 176 well-defined renal tumor samples including 113 
(64.2%) clear cell RCCs (ccRCCs), 32 (18.2%) papillary RCCs, and 31 (17.6%) chromophobe 
RCCs using immunohistochemistry on tissue microarrays. The association between hTERT 
expression and clinicopathologic parameters as well as survival outcomes were then analyzed. 
There was a statistically significant difference in terms of hTERT expression among various 
RCC subtypes. In ccRCC, increased expression of hTERT was significantly associated with 
advanced stage, higher grade, presence of microvascular invasion (MVI), lymph node invasion 
(LNI), and metastasis. Moreover, in the multivariate analysis, tumor stage and tumor size were 
independent predictors of the overall survival (OS). Additionally,  expression of hTERT was 
found to be a significant predictor of worse OS (P = 0.013) in the univariate analysis in ccRCC 
cases. In papillary carcinoma samples, significant association was detected between hTERT 
expression and tumor stage as well as metastasis, however, in chromophobe RCC, no significant 
association was found. We showed that hTERT protein expression was associated with more 
aggressive tumor behavior and more advanced disease in ccRCC patients. Also, hTERT may be 
a novel negative (?) prognostic indicator of the overall survival in these cases. 
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Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney (80% to 90%), 
accounting for a total of 2% to 3% of adult malignancies, and is the most fatal urologic cancer [1]. 
The 2004 World Health Organization (WHO) classified RCC into several subtypes: the most 
common subtype is clear cell renal cell carcinoma (ccRCC), representing 75% to 80% of primary 
renal malignancies followed by papillary and chromophobe RCC accounting for 10% to 15% and 
5% of renal cancers, respectively [2]. It is estimated that there will be 63,990 new cases of RCC 
in the United States and 14,400 related deaths in 2017[3]. Despite the recent advances in the 
diagnosis and treatment of RCC such as using tyrosine kinase and mTOR kinase inhibitors [4,5], 
up to 30% of RCC patients present with distant metastatic disease and 20% to 40% develop 
recurrent disease after surgery, therefore, RCC is still one of the deadliest forms of malignancies 
with a continued increase in incidence [6].  
Human telomerase is a ribonucleoprotein enzyme consisting of two main components: catalytic 
component, human telomerase reverse-transcriptase (hTERT) and human telomerase RNA 
molecule (hTR), in addition to telomerase-associated proteins hTEP1, p23, Hsp90, and dyskerin. 
Telomerase adds the telomere repeat sequence (TTAGGG)n to the 3' end of telomeres using its 
RNA as a template and hTERT [7]. Evidence shows that telomerase is expressed in 85% of 
malignancies, and the level of its activity is higher in advanced and metastatic tumors. While it is 
absent or barely detectable in most human normal somatic cells and in germ cells, stem cells, and 
cardiovascular cells express significant detectable levels of telomerase [8-10]. 
A previous study has shown that hTERT, an active component of telomerase and responsible for 
its catalytic activity, has other functions unrelated to its reverse transcriptase activity, such as 
increasing the anti-apoptotic capacity, enhancing DNA repair, maintaining stem cells and 
regulating gene expression [11].  
A number of clinical studies have been performed to evaluate the association between telomerase 
activity and clinicopathological parameters in renal cancer showing that telomerase activity level 
correlates with progression of RCC [12-14]. However, we could not find any data regarding 
hTERT protein expression patterns and its association with clinicopathological parameters and 
survival in RCC patients. 
In view of these facts, the present study was designed to investigate for the first time the expression 
levels and potential prognostic role of hTERT protein in a series of RCC clinical tumor samples, 
composed of clear cell, papillary, and chromophobe RCC using tissue microarray (TMA) method. 
Materials and methods 
Patient characteristics and tumor samples 
A total of 176 paraffin-embedded tissues from RCC clinical tumor samples were included in this 
study. These specimens were collected from the Hasheminejad hospital, a major referral 
university-based urology-nephrology center in Tehran, Iran, in the time period of 2010 to 2015. 
All samples were collected from patients who had undergone radical nephrectomy and had no 
history of radiation therapy. These samples comprised of various subtypes of RCC including clear 
cell, papillary, and chromophobe RCC. The hematoxylin and eosin (H & E) stained slides and 
medical archival records were retrieved to obtain clinicopathological parameters including age, 
gender, tumor size (maximum tumor diameter), tumor stage, and nuclear grade. In addition, the 
presence of necrosis, distant metastasis, the involvement of regional lymph nodes, renal vein, sinus 
and pelvis, Gerota’s fascia, and microvascular invasion (MVI) were recorded. Information about 
patients’ outcomes including the time between radical nephrectomy and cancer-related death or 
last follow-up (if death did not occur) were also recorded. The stage was defined based on the 
pTNM classification for renal cell carcinomas [15]. 
Immunohistochemistry (IHC) for hTERT protein expression 
Representative tissue cores from formalin-fixed and paraffin-embedded RCC tumors were selected 
by an experienced pathologist and collected in a tissue microarray (TMA), as recently published 
[16]. 
Briefly, all TMA sections were deparaffinized at 60 °C for 20 minutes and dehydrated with graded 
alcohol. Endogenous peroxides and non-reactive staining were blocked with 3% H2O2 for 20 
minutes at room temperature. After washing the tissue sections three times, antigen retrieval was 
performed by immersing the tissues in citrate buffer (pH =6.0) for 10 minutes in an autoclave. The 
tissue sections were incubated with primary antibody, anti-Telomerase reverse transcriptase 
antibody (ab183105, abcam, dilution: 1/500), overnight at 4°C. TMA slides were then incubated 
with anti-rabbit/anti-mouse Envision (Dako, Denmark) as a secondary antibody for 30 minutes. 
Staining patterns were visualized by exposure to 3, 3′-diaminobenzidine (DAB, Dako) followed 
by counterstaining with hematoxylin visualize antigen (Dako). Finally, the slides were dehydrated 
in alcohol, cleared in xylene (Dako), and mounted for examination. In each run of the experiment, 
human tonsillar tissue was used as a positive control, and for a negative control, the primary 
antibody was replaced with Tris-buffered saline.  
Evaluation of immunostaining 
Immunostaining of telomerase reverse transcriptase (hTERT) was independently evaluated by two 
pathologists (M.A. and M.A.) who were blinded to the patients’ outcome and pathological 
information. A consensus was achieved for all samples. The intensity of staining was scored by 
applying a semi-quantitative system, ranging from negative to strong as follows: 0 = negative, 1= 
weak, 2 = moderate, and 3 = strong. The percentage of positive cells was categorized according to 
the positive tumor cells as follows: Group 1:  less than 25% positive cells, Group 2: 25%  to 50% 
positive cells, Group 3:  51% to 75% positive cells, and Group 4: more than 75% positive cells. 
To compare all the available data, we assigned an overall histochemical score (H-score) to each 
case by multiplying the intensity score by the percentage of positive cells, which yielded a range 
from 0 to 300. In this study, median H- score was chosen to categorize samples as with high or 
low telomerase reverse transcriptase expression. 
Statistical analysis 
Data were analyzed using the "statistical software SPSS, version 20.0. Armonk, NY: IBM 
Corp".We reported the categorical data as N(%) and quantitative data as mean (SD). Comparison 
of hTERT expression in ccRCC, papillary, and chromophobe RCC samples was done using 
Kruskal-Wallis & Mann-Whitney U tests, for pairwise comparison between groups based on 
Bonferroni adjustment. Moreover, Pearson’s χ2 and Spearman’s correlation tests were used to 
analyze the significance of association and correlation between hTERT expression and 
clinicopathological parameters. Overall survival (OS) curves were drawn using the Kaplan-Meier 
method and log-rank test was used to compare the estimated curves between groups. The Cox 
proportional hazards regression model was applied to determine which variables affected OS. 
Variables that significantly affected survival in univariate analysis were included in multivariable 
analyzes. A p-value of ≤ 0.05 was considered statistically significant. 
Results 
Patient characteristics 
Of the total 176 samples included, 113 (64.2%) were ccRCC, 32 (18.2%) papillary, and 31 (17.6%) 
chromophobe RCC. The study population consisted of 123 (69.9%) male and 53 (30.1%) female 
patients, with a male/female ratio of 2.3. The mean age of patients was 55 (SD=13) years (ranging 
from 25 to 82); 85 (48.3%) patients were younger than 55 and 91 (51.7%) over 55 years old. 
Tumor size ranged from 1 to 21 cm in the largest diameter and tumors were classified into four 
groups: Group 1: 0 to 4 cm 34 (19.3%), Group 2: 4.1 to 7 cm 63 (35.8%), Group 3: 7.1 to 10 cm 
40 (22.7%), and Group 4: >10.1 cm 39 (22.2%). 
In this study, 90 (51.1%) patients had low nuclear grade tumors, (grade II), 48 (27.3%) grade III 
tumors, and 7 (4.0%) high nuclear grade tumors (grade IV).  
Moreover, 45 (25.6%) cases were stage I, 13 (7.4%) stage II, 103 (58.5%) stage III, and 15 (8.5%) 
stage IV. 
Regional lymph node involvement was found in 12 (6.8%) cases; 33 (18.8%) cases had MVI, 100 
(56.8%) renal sinus fat involvement, and 74 (42.0%) cases had tumor necrosis. Moreover, 37 
(21.0%) cases showed subsequent metastasis during the follow-up period. Other less frequent sites 
of involvement were as follow: renal vein invasion (9; 5.1%), renal pelvis invasion (13; 7.4%), 
perirenal fat invasion (30; 17.0%), and Gerota’s fascia invasion (4; 2.3%). 
The clinicopathological features of patients are summarized in Table 1 based on the subtypes of 
RCC. It was agreed that chromophobe RCC should not be graded [17]. 
Comparison of hTERT protein expression in RCC subtypes 
hTERT was expressed with variable intensities in the nucleus and partly in the cytoplasm of the 
RCC samples (Figure 1). Patients were classified into two groups as described earlier. 
Of 176 RCC samples stained for hTERT, 4 (2.3%) did not show any staining, whereas weak, 
moderate, and strong staining intensities were observed in 52 (29.5%), 70 (39.8%), and 50 (28.4%) 
cases, respectively. The evaluation of hTERT expression based on the H- score values 
demonstrated that low expression of hTERT was found in 90 (51.5%) and high expression was 
found in 86 (48.9%) of RCC samples. Pearson’s chi-square test showed a statistical significant 
association between hTERT expression and RCC subtypes (Pearson’s χ2, P < 0.001) (Table 2). 
The nonparametric Kruskal –Wallis & Mann–Whitney U tests were used to compare differences 
between hTERT expressions among the three tumor subtypes. Results of Kruskal –Wallis test 
indicated a statistically significant difference between the various levels of hTERT expression in 
different RCC subtypes (P < 0.001). Using the Mann–Whitney U test, a statistically significant 
difference in the level of hTERT expression between ccRCC and chromophobe samples and also 
papillary and chromophobe RCC was found (P < 0.001) (Figure 2). 
Associations between hTERT protein expression and clinicopathological characteristics in 
RCC  
Pearson’s chi-square test showed that significant association between hTERT expression and 
tumor stage (P < 0.001) as well as nuclear grade (P =0.028) in the ccRCC subtype. In addition, 
there was a significant association between higher levels of hTERT expression and tumor size (P 
= 0.050), MVI (P = 0.005), lymph node invasion (LNI) (P = 0.020), renal pelvis involvement (P = 
0.010), renal sinus fat involvement (P = 0.002), Gerota’s fascia invasion (P = 0.012), and distant 
metastasis (P = 0.031)( Table 3). 
Kruskal–Wallis test indicated that a statistically significant difference (P < 0.001) between median 
hTERT expression and various tumor stages (I–IV). The median expression level of hTERT was 
100 in stage I, 71 in stage II, 178 in stage III, and 238 in stage IV. Moreover, Mann–Whitney U 
test showed highly significant difference in the levels of hTERT expression between stages I and 
IV (P < 0.001) (Figure 3A).  
The Kruskal–Wallis & Mann–Whitney U tests also showed statistically significant difference 
between hTERT expression and MVI (P = 0.005) as well as LNI (P = 0.030) (Figures 3B, 3C).  
Bivariate analysis showed a significant direct correlation between hTERT expression and 
advanced tumor stage (P < 0.001) as well as nuclear grade (P= 0.049). In addition, statistically 
significant correlation was observed between hTERT expression and MVI (P= 0.005), renal pelvis 
involvement (P = 0.010), renal sinus fat involvement (P = 0.002), Gerota’s fascia invasion (P = 
0.012), tumor size ( P = 0.017), and distant metastasis (P = 0.031).  
In papillary RCC, there was significant association between hTERT expression and tumor stage 
(P = 0.033), renal sinus fat involvement (P = 0.009), and metastasis (P = 0.010) (Table 4). In 
chromophobe RCC, we did not find any association between hTERT expression and 
clinicopathological features.   
Prognostic value of hTERT expression for clinical outcome in RCC 
Among 113 ccRCC samples included in this study, metastasis occurred in 28 (24.8 %) patients. 
During the follow-up period time, disease-related death was observed in 22 patients (19.5 %).  
Kaplan-Meier survival analysis on these RCC patients, with median follow-up of 42 months 
(ranging from 1–77m) showed a significant difference between OS among the high and low 
hTERT expressing patient groups (Log Rank test, P= 0.013). The mean OS for patients with the 
high and low hTERT expression was 56 (SD=4.6) and 66 (SD=2.5) months, respectively (Figure 
4A). 
The 5-year OS for the high and low hTERT expressing patients was 68% and 87%, respectively 
(P=0.013). 
The significant risk factors affecting the OS in univariate analysis included hTERT expression (P= 
0.01), nuclear grade (P < 0.002), tumor stage (P < 0.001), and tumor size (P < 0.001). Other 
clinicopathologic parameters did not significantly affect the OS in ccRCC patients. In multivariate 
analysis, tumor stage (P=0.044) and tumor size (P=0.011) were significantly related to the OS in 
ccRCC patients (Table 5). 
In the papillary and chromophobe RCC patients, Kaplan–Meier survival analysis showed that high 
levels of hTERT expression is not  significantly related to the OS(Figures 4B, C). 
 Discussion 
Telomerase is an attractive and ideal target for therapy due to overexpression in the majority of 
malignancies and low or non-expression in most somatic cells [10,9]. 
Several studies have previously investigated the levels of telomerase activity and hTERT mRNA 
expression in RCC [12-14,18], whereas we could not find any study addressing the hTERT protein 
expression in RCC patients. 
In the present study for the first time, the expression levels of hTERT protein was investigated in 
a well- characterized series of 176 RCC tissue samples from patients treated with radical 
nephrectomy. There was highly significant associations between the level of hTERT expression 
and RCC subtype. Moreover, a significant difference was observed in the levels of hTERT 
expression between ccRCC and chromophobe samples and also papillary and chromophobe RCC. 
These findings demonstrate that hTERT has different expression patterns among various subtypes 
of RCC, implying molecular mechanisms which lead to cellular immortality may differ according 
to tumor subtype [19]. 
In this study, we showed that hTERT protein expression is associated with more advanced tumor 
stage and higher tumor grade in ccRCC. The tumor stage and nuclear grade are the most reliable 
prognostic factors in RCC and tumors with a high Fuhrman grade have a more aggressive 
phenotype [20]. Importantly, we observed that the median expression of hTERT was higher in 
more advanced tumor stages (stage III and stage IV) when compared to the stages I and II, which 
depicts the association of hTERT protein expression with aggressiveness of ccRCC. Also, the 
tumor stage and Fuhram grade were significantly correlated with poor prognosis, however, tumor 
stage was found to be independent prognostic factor in multivariate analysis. The current study 
demonstrated a trend towards the association of increased hTERT protein expression and stage. 
Our result is in agreement with a study performed by Mekhail at al.[14] who showed that 
relationship between telomerase activity and tumor stage. In addition, significant association was 
found between the level of hTERT expression and distant metastasis. This observation is also 
consistent with a previous report based on the measurement of serum hTERT enzyme activity 
showing that its levels are associated with more advanced tumors stage and distant metastasis [21]. 
Moreover, the presence of statistically significant association between expression levels of hTERT 
and tumor size, renal pelvis and renal sinus fat involvement, and Gerota’s fascia invasion showed 
that hTERT protein expression is related to the degree of malignancy and more advanced disease 
in ccRCC. Evidence shows that hTERT plays a role in tumor invasion and metastasis by promoting 
epithelial mesenchymal transition (EMT). Also, hTERT can activate the WNT/beta-catenin 
signaling pathway, therefore, it may contribute to cancer stem cell (CSC) maintenance [22]. CSCs 
are subpopulation among the tumor cells that have the ability to self-renew and have high tumor-
initiating potential, and thus, they are able to drive cancer maintenance, progression, and metastasis 
[23]. Moreover, it is known that EMT generates cancer cells with stem cell-like characteristics; 
stem-like cells express markers associated with EMT; and the diversity and abundance of CSCs in 
solid tumors allows cells the ability to undergo EMT and cancer progression [24]. Castelo-Branco 
et al. showed that CSCs have significantly higher levels of hTERT expression and extremely short 
telomeres compared with the normal tissue stem cells [25]. CD133 as a CSC marker, was more 
highly expressed in hTERT-immortalized cells than in primary prostate cells [26]. 
In our study, tumor size was found to be independent prognostic indicator in multivariate analysis, 
in contrast with some previous studies which could not find any significant association between 
telomerase activity and tumor size [13,27]. Investigations have shown that tumor size has an 
important clinical and pathologic feature for patients with RCC and is significantly associated with 
risk of metastasis [28,29]. 
RCC is clinically recognized as a highly vascularized tumor, and one of the features of ccRCC is 
the presence of branching, thin-walled vessels in between the tumor cells [17]. Interestingly, we 
observed higher level of hTERT protein in this tumor subtype associated with higher MVI. Lang 
at al.[30] showed that MVI is related to cancer progression and survival in RCC and has more 
effects on prognosis compared to the macroscopic renal vein or vena cava invasion after treatment 
by radical nephrectomy. Several studies have reported the expression of hTERT as a potential 
factor in enhancing angiogenesis due to possible regulatory interactions with VEGF (Vascular 
endothelial growth factor)[31]. VEGF plays a pivotal role in tumor growth and  progression in 
RCC [32,33]. LNI is also one of the other important prognostic factors in RCC. A previous study 
showed that LNI was independently associated with cancer specific survival after surgical 
resection and provides the strongest predictor of prognosis in patients without MVI [34].  
Our results are in agreement with the previous studies which concluded that hTERT protein has 
an iportant role in advanced malignancy on some cancer types including breast cancer, gastric 
cancer, colorectal cancer, meningiomas, and spinal chordoma [35-39].  
We found for the first time that tumors with higher expression of hTERT tend to have a worse 
prognosis compared to those with low expression. In addition, ccRCC patients who expressed 
higher level of hTERT had shorter 5-year overall survival compared with those with low 
expression. To our knowledge, this is the first study showing that hTERT protein expression is a 
prognostic marker in ccRCC, although without an independent significance in the multivariate 
analysis. Previous studies which focused on hTERT mRNA expression in RCC samples concluded 
that telomerase activity, was not related to prognosis [12-14]. A possible explanation for this 
discrepancy is post-transcriptional modification of hTERT mRNA.  
In this study, we examined hTERT protein expression patterns in 32 papillary and 31 chromophobe 
RCC samples which are less frequent variants of RCC. We showed that in papillary RCC, there 
was significant association between increased hTERT protein expression and more advanced 
disease. However, there was not statistically significant association between hTERT protein 
expression and patients’ outcomes. A larger sample size may be required to clearly address this 
issue. Moreover, in chromophobe RCC, no significant association was found between hTERT 
expression and tumor aggressiveness. This finding is in agreement with a previous study that 
telomerase was found only infrequently in chromophobe RCC [40]. ccRCC is known to be more 
aggressive and associated poorer prognosis than papillary and chromophobe RCC subtypes [41]. 
Almost all ccRCCs have deletions in the short arm of chromosome 3, resulting in mutations of the 
von Hippel-Lindau (VHL) gene which are frequent in ccRCC and are not observed in any other 
subtypes [42]. Evidence shows that mutations of VHL tumor suppressor gene leads to loss of 
function of the VHL tumor suppressor protein and consequent activation of the hypoxia pathway 
via the hypoxia-inducible factors [43] like transcription factor HIF1α which plays an important 
role in development of ccRCC and upregulates a series of hypoxia-responsive genes including 
VEGF which has a pivotal role in ccRCC tumorigenesis [44]. Also, it has been previously reported 
that transcription factor HIF1α induces hTERT expression and the level of hTERT is increased 
under hypoxic conditions [45]. From these findings we are able to conclude that hTERT protein 
expression may be a novel prognostic indicator of worse outcome in patients with ccRCC,  if 
follow up time is more prolonged. In addition, evaluation of hTERT protein expression indicate 
more aggressive tumor behavior and more advanced disease in ccRCC cases. Thus, evaluation of 
hTERT protein expression can be useful for predicting of tumor invasiveness in ccRCC patients. 
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Legends for figures 
Figure 1. Immunohistochemical analysis of hTERT expression in renal cell carcinoma (RCC) 
samples. hTERT expression in clear cell RCC: high expression (A, A-1) and low expression (B, 
B-1). hTERT expression in papillary RCC: (C, C1) and in chromophobe RCC (D, D1). Figures 
are shown with a magnification of ×100 and ×200 
Figure 2. Analysis of hTERT expression level in different renal cell carcinoma (RCC) subtypes 
including clear cell, chromophobe, and papillary RCC using Mann–Whitney U test. Based on the 
standard definitions, each box-plot shows the median (bold line), interquartile line (box), and 
outlier observation (circle). 
Figure 3. Box plot analysis of hTERT expression levels in stage I to IV (A), microvascular 
invasion (MVI) (B), and lymph node invasion (LNI) (C) in ccRCC, using Mann–Whitney U test. 
Based on the standard definitions, each box-plot shows the median (bold line) and interquartile 
lines (box). 
Figure 4. Kaplan-Meier curves for overall survival (OS) based on hTERT protein expression 
level in ccRCC. In ccRCC patients, higher level of hTERT protein expression was associated 
with shorter overall survival compared to the tumors with low expression of this protein (A). In 
the papillary and chromophobe RCC patients, Kaplan–Meier survival analysis showed that high 
levels of hTERT expression is not significantly related to the OS (B, C). 
 
 
